The IMPACT study evaluates targeted PCa screening for men carrying genetic alterations in BRCA1, BRCA2, and Lynch syndrome genes (MSH2, MSH6, and MLH1), aiming to detect clinically significant PCa (csPCa) using a PSA threshold of 3.0 ng/ml.10, 11. The gene discussed is MSH6; the disease is posterior cortical atrophy.